- Conditions
- Neurotrophic Keratitis
- Interventions
- CSB-001 Ophthalmic Solution 0.1%, Vehicle Control
- Biological
- Lead sponsor
- Claris Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 45
- States / cities
- Cave Creek, Arizona • Loma Linda, California • Los Angeles, California + 40 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–15
of 15
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Netarsudil 0.02% Ophthalmic Solution, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, AR-17043 Vehicle
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 12
- States / cities
- Garden Grove, California • Inglewood, California • Newport Beach, California + 9 more
- Conditions
- Dry Eye
- Interventions
- EBI-005, Placebo
- Drug
- Lead sponsor
- Eleven Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Newport Beach, California • Hamden, Connecticut + 9 more
- Conditions
- Myopia, Progressive
- Interventions
- OT-101 Ophthalmic Solution, Vehicle
- Drug
- Lead sponsor
- Ocumension (Hong Kong) Limited
- Other
- Eligibility
- 3 Years to 15 Years
- Enrollment
- 678 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 15
- States / cities
- Colorado Springs, Colorado • Fort Collins, Colorado • Gainesville, Florida + 12 more
- Conditions
- Allergic Conjunctivitis
- Interventions
- Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo
- Drug
- Lead sponsor
- Fovea Pharmaceuticals SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Ocular Hyperemia
- Interventions
- Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Dry Eye
- Interventions
- Vehicle, SDP-4 Ophthalmic Solution (1.0%)
- Drug
- Lead sponsor
- Silk Technologies, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 5
- States / cities
- Garden Grove, California • Murrieta, California • Newport Beach, California + 2 more
- Conditions
- Dry Eye Disease (DED)
- Interventions
- Active Comparator EBI-005, Placebo Comparator
- Drug
- Lead sponsor
- Eleven Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 45
- States / cities
- Chandler, Arizona • Mesa, Arizona • Little Rock, Arkansas + 38 more
- Conditions
- Dry Eye
- Interventions
- SDP-4 Ophthalmic Solution (0.1%), SDP-4 Ophthalmic Solution (1.0%), SDP-4 Ophthalmic Solution (3.0%), Vehicle
- Drug
- Lead sponsor
- Silk Technologies, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 26
- States / cities
- Azusa, California • Garden Grove, California • Mission Hills, California + 22 more
- Conditions
- Ocular Redness, Eye Irritation
- Interventions
- FID 123320 Ophthalmic Solution, Vehicle
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 10
- States / cities
- Azusa, California • Newport Beach, California • Colorado Springs, Colorado + 7 more
- Conditions
- Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension (OHT)
- Interventions
- Experimental: QLS-111 ophthalmic solution, (0.015%), Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%), QLS-111 ophthalmic vehicle solution
- Drug · Other
- Lead sponsor
- Qlaris Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Roswell, Georgia
- Conditions
- Seasonal Allergic Conjunctivitis
- Interventions
- Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025%, Experimental: Vehicle ophthalmic solution
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 6
- States / cities
- Louisville, Kentucky • Andover, Massachusetts • Goodlettsville, Tennessee + 3 more
- Conditions
- Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
- Interventions
- QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%, QLS-111 vehicle ophthalmic solution
- Drug
- Lead sponsor
- Qlaris Bio, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ocular Redness
- Interventions
- Apraclonidine Hydrochloride Ophthalmic Solution, Vehicle
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Glendale, California • Garner, North Carolina • Cranberry Township, Pennsylvania + 2 more
- Conditions
- Ocular Hyperemia
- Interventions
- Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas